BiotechTube
Home/Pipeline/Measovir®-based Prophylactic Vaccine (with Unither)

Measovir®-based Prophylactic Vaccine (with Unither)

Undisclosed

Research/Pre-clinicalEarly-stage collaboration

Key Facts

Indication
Undisclosed
Phase
Research/Pre-clinical
Status
Early-stage collaboration
Company
Oncovita

About Oncovita

Oncovita is a spin-off from Institut Pasteur dedicated to developing life-saving cancer treatments using its proprietary Measovir® platform, a modified measles virus vector. The company has secured exclusive worldwide licensing rights from Institut Pasteur and is advancing its lead candidate, MVdeltaC, for pleural mesothelioma, which has received FDA Orphan Drug Designation. Led by a seasoned management team, Oncovita is building a pipeline of oncolytic virus candidates and has established strategic partnerships with entities like Infinitusbio.AI and Unither Pharmaceuticals to accelerate development.

View full company profile

Therapeutic Areas

Oncology

Other Undisclosed Drugs

DrugCompanyPhase
ASPEN Study ProgramInsmedPhase 3
ARISE Study ProgramInsmedPhase 3
MGL-2086Madrigal PharmaceuticalsPhase 1
Innovative Proprietary/Licensed ProductsLaboratorios Farmaceuticos RoviVarious
Undisclosed Partnered ProgramSepternaDiscovery
Undisclosed Cell TherapyImmix BiopharmaPre-clinical
HTL0039732Nxera PharmaPreclinical
LYT-310PureTech HealthPreclinical
Bispecific (Undisclosed)MacroGenicsPreclinical
Sec61 Portfolio AssetsKezar Life SciencesPreclinical
WTX-518Werewolf TherapeuticsPreclinical
WTX-712Werewolf TherapeuticsPreclinical